News Quantified

RGNX – regenxbio inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

REGENXBIO (NASDAQ:RGNX) was given a new $45.00 price target on by analysts at Stifel Nicolaus.

REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]

REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

REGENXBIO (NASDAQ:RGNX) had its "outperform" rating reaffirmed by analysts at Leerink Partners.

REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript [Yahoo! Finance]

-3.8%

BEAT

-6.8%

MISS

2.3%

MISS

2.6%

BEAT

Leerink Partners

Leerink Partners

Chardan Capital

Chardan Capital

Form EFFECT REGENXBIO Inc.

Form S-3 REGENXBIO Inc.

Form 8-K REGENXBIO Inc. For: Nov 06

Form 10-Q REGENXBIO Inc. For: Sep 30

Form 4 REGENXBIO Inc. For: Oct 09 Filed by: Simpson Curran

Top News Gainers

3/19 Regenxbio Inc (NASDAQ: RGNX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 12.1%

4/8 Form DEF 14A REGENXBIO Inc. For: May 29 8.8%

10/15 Form 8-K REGENXBIO Inc. For: Oct 11 8.8%

1/15 Regenxbio Inc (NASDAQ: RGNX) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. 7.1%

11/6 The FDA Paused This Biotech's Gene Therapy Study — And Shares Tumbled [Investor's Business Daily] 6.9%

8/28 REGENXBIO to Present at Upcoming Investor Conferences 5.4%

4/22 REGENXBIO Announces Additional Positive Long-term and Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD 5.0%

12/12 We Think REGENXBIO (NASDAQ:RGNX) Can Afford To Drive Business Growth [Yahoo! Finance News] 4.8%

7/17 Regenxbio Inc (NASDAQ: RGNX) was given a new $84.00 price target on by analysts at Morgan Stanley. They now have a "buy" rating on the stock. 4.4%

1/9 REGENXBIO Reports Continued Progress Across Programs in Year-End 2019 Corporate Update 4.2%

Top News Decliners

3/11 Regenxbio Inc (NASDAQ: RGNX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -17.1%

2/26 Form 8-K REGENXBIO Inc. For: Feb 26 -14.8%

10/30 Regenxbio's Wet AMD Data Is Encouraging, With Majority Of Patients Free Of Rescue Injections [Seeking Alpha] -12.0%

10/11 Big Pharma Has Mad Love For These 2 Biotechs [The Motley Fool] -11.9%

3/6 Form SC 13G REGENXBIO Inc. Filed by: GIC Private Ltd -10.2%

3/31 REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder -10.0%

5/30 REGENXBIO Announces Completion of Dosing for Phase I/IIa Clinical Trial of RGX-314 in Wet AMD -9.9%

5/7 Q1/2019 3/31/2019 EPS -0.890 ZacksConsensus -0.850 ActVsEst (0.040) - Miss -8.5%

4/30 REGENXBIO To Host Conference Call on May 7 to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights -8.4%

8/8 Regenxbio Inc (NASDAQ: RGNX) was given a new $79.00 price target on by analysts at Evercore ISI. They now have a "buy" rating on the stock. -6.2%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day